Corcept Therapeutics Inc. – Chart, Kurs & Nachrichten (NASDAQ:CORT)

Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Market Capitalization 74.6 M
Employee 730
Founded 1998
CEO N/A
Website www.corcept.com
Headquarter Delaware, United States
FIGI BBG000BKJG33
Industry Biotechnologie

Gesamtumsatz

Jahresüberschuss

Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)

Gesamtverschuldung

Freier Cashflow

Zahlungsmittel und Zahlungsmitteläquivalente

Kurs-Gewinn-Verhältnis

42.44

Preis-Umsatz-Verhältnis

5.48

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated - Common Stock

Nachrichten

Corcept Therapeutics: Chief Accounting Officer veräußert Aktien im Wert von 325.000 $

Corcept-Präsident verkauft Aktien im Wert von 4,9 Mio. $

Corcept legt überzeugende Überlebensdaten für Eierstockkrebs-Behandlung vor

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

Chip Stock Strength Lifts the Broader Market

Stocks Pressured by Signs of Resurgent Inflation

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement (NASDAQ:CORT)

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates